Mylan Can't Get Top Court Review Of $76M Antitrust Ruling
By Abigail Rubenstein ( October 3, 2011, 3:10 PM EDT) -- The U.S. Supreme Court on Monday declined to hear Mylan Laboratories Inc.'s appeal of a $76 million antitrust verdict over licensing agreements for anti-anxiety medications based on Mylan's claims that the insurance company plaintiffs could not establish subject matter jurisdiction....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.